A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.

被引：0

作者：

Rizzieri, D.

Krug, U.

Schlenk, R. F.

Vey, N.

Thomas, X. G.

Huguet, F.

Johansen, M.

Jacobsen, T. F.

机构：

[1] Duke Univ, Med Ctr, Durham, NC USA

[2] Univ Hosp Muenster, Munster, Germany

[3] Univ Ulm, D-89069 Ulm, Germany

[4] Inst J Paoli I Calmettes, F-13009 Marseille, France

[5] Hosp Edouard Herriot, Lyon, France

[6] Hosp Purpan, Toulouse, France

[7] Clavis Pharma, Oslo, Norway

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.tps207

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS207

引用

页数：1